PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY 1,481.00
+70.50 (5.00%)
At close: Mar 6, 2026
PeptiDream Revenue
In the year 2025, PeptiDream had annual revenue of 18.52B JPY, down -60.32%. PeptiDream had revenue of 5.66B in the quarter ending December 31, 2025, with 11.68% growth.
Revenue
18.52B
Revenue Growth
-60.32%
P/S Ratio
10.33
Revenue / Employee
24.66M
Employees
751
Market Cap
191.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.52B | -28.15B | -60.32% |
| Dec 31, 2024 | 46.68B | 17.96B | 62.57% |
| Dec 31, 2023 | 28.71B | 1.86B | 6.93% |
| Dec 31, 2022 | 26.85B | 17.49B | 186.70% |
| Dec 31, 2021 | 9.37B | -2.31B | -19.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takara Bio | 44.15B |
| Nxera Pharma | 29.62B |
| GNI Group | 26.84B |
| RaQualia Pharma | 3.98B |
| Japan Tissue Engineering | 2.26B |
| AnGes | 874.00M |
| Cuorips | 356.00M |
| Renascience | 107.00M |
PeptiDream News
- 4 weeks ago - Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire
- 2 months ago - PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis - Business Wire